As of May 27, 2025, Sutro Biopharma Inc (STRO) reports a EV/EBITDA of 0.43.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Sutro Biopharma Inc's EV/EBITDA to Peers
To better understand Sutro Biopharma Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Sutro Biopharma Inc (STRO) | 0.43 |
| MannKind Corp (MNKD) | 21.16 |
| Abbvie Inc (ABBV) | 17.74 |
| Theratechnologies Inc (TH.TO) | 15.62 |
| Regeneron Pharmaceuticals Inc (REGN) | 14.51 |
| Amgen Inc (AMGN) | 14.47 |
Compared to its competitors, Sutro Biopharma Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.